ACSL5 suppresses pancreatic cancer progression and gemcitabine resistance by regulating n-6 docosapentaenoic acid metabolism
Gemcitabine (GEM) resistance remains a major challenge in pancreatic ductal adenocarcinoma (PDAC) treatment. Metabolic reprogramming is a hallmark of tumors, and imbalance in lipid metabolism promotes tumor progression and drug resistance. This study aims to elucidate the mechanism of Acyl-CoA Synthetase Long C...